CD3 engagement as a new strategy for allogeneic “off-the-shelf” T cell therapy

Allogeneic “off-the-shelf” (OTS) chimeric antigen receptor T cells (CAR-T cells) hold promise for more accessible CAR-T therapy. Here, we report a novel and simple way to make allogeneic OTS T cells targeting cancer. By engineering T cells with a bispecific T cell engager (BiTE), both TCRαβ and CD3ε...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Gongbo, Reid, Kayla M., Spitler, Kristen, Beatty, Nolan, Boucher, Justin, Davila, Marco L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919219/
https://www.ncbi.nlm.nih.gov/pubmed/35317526
http://dx.doi.org/10.1016/j.omto.2022.02.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919219/
https://www.ncbi.nlm.nih.gov/pubmed/35317526
http://dx.doi.org/10.1016/j.omto.2022.02.024

Ejemplares similares